Organogenesis Holdings

Organogenesis Holdings, Inc. is a regenerative medical company. It focuses on the development, manufacture and commercialization of product solutions for the advanced wound care, surgical and sports medicine markets. The company was founded in 1985 and is headquartered in Canton, MA.

Earnings data Q4 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Organogenesis focuses on advanced wound products. The company's second-quarter revenue and net income were down year over year.

Why Shares of Organogenesis Holdings Are Up Thursday

CANTON, Mass., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, applauds today's decision by the three Medicare Administrative Contractors (MACs) to withdraw the final local coverage determinations (LCDs) for Skin Substitute Grafts/Cellular and/or Tissue-Based Products for the Treatment of Diabetic Foot Ulcers (DFU) and Venous Leg Ulcers (VLU) scheduled to take effect on October 1.

Organogenesis Applauds Withdrawal of Local Coverage Determinations by Novitas, First Coast Service Options and CGS

CANTON, Mass. , Sept. 06, 2023 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that company management will participate in the Morgan Stanley 21st Annual Global Healthcare Conference, which is being held at the Sheraton New York Times Square Hotel in New York, NY from September 11th-13th. Management will host a fireside chat to discuss business matters on Monday, September 11th at 8:00 a.m. Eastern Time.

Organogenesis Holdings Inc. to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

Organogenesis saw revenue and net income drop year over year. The company withdrew annual guidance.

Why Shares of Organogenesis Holdings Are Dropping Thursday

CANTON, Mass., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the second quarter ended June 30th, 2023.

Organogenesis Holdings Inc. Reports Second Quarter 2023 Financial Results; Withdraws Fiscal Year 2023 Guidance

Blade Air Mobility

The Metals Co

While the market offers ample opportunities for wild speculation, there's something about favored penny stocks by analysts that arouses interest. Don't get me wrong – whenever you're dealing with enterprises in this troubled arena, downside threats are never too far away.

3 Penny Stocks That Wall Street Analysts Can't Get Enough Of

Organogenesis is a solid player in the surgical care product market. Over its long existence, it has developed an important slate of core competencies. Small-cap biotech is a risky area, none more so than Organogenesis.

Organogenesis: Solid Revenue Generation From A Hyper-Trading Wound Care Company

Dragonfly Energy Holdings Corp

Canoo

Rigel Pharmaceuticals

Rockwell Medical

Interested in discovering the top penny stocks to invest in? You're certainly not the only one.

7 Cheap Penny Stocks to Buy According To Analysts, Targets Up To 1,090%

Want to know how to find the best penny stocks to buy now? Of course you do and you're not alone.

4 Cheap Penny Stocks to Buy According To Analysts, Targets Up To 230%

CANTON, Mass., July 10, 2023 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that second quarter of fiscal year 2023 financial results will be reported after the market closes on Wednesday, August 9th.

Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2023 Financial Results on August 9, 2023

An analyst updated Organogenesis' price target. Competitor Integra LifeSciences said Tuesday it was recalling a product.

Why Shares of Organogenesis Climbed Wednesday

Cabaletta Bio

Community Health Systems

Exact Sciences

Moderna

Novavax

Pfizer

Ultragenyx Pharmaceutical

Viking Therapeutics

TipRanks' analyst ranking service ranks the top Wall Street firms of the past decade.

TipRanks reveals the top 10 health care sector analysts of the past decade

Organogenesis said it expects sales to rise between 1% and 3% this year. The company said revenue rose by 10% year over year in the first quarter.

Why Shares of Organogenesis Holdings Jumped Thursday

Organogenesis Holdings Inc. (NASDAQ:ORGO ) Q1 2023 Earnings Conference Call May 10, 2023 5:00 PM ET Company Participants Gary Gillheeney - President and CEO Dave Francisco - CFO Conference Call Participants Ryan Zimmerman - BTIG Operator Welcome, ladies and gentlemen to the First Quarter of Fiscal Year 2023 Earnings Conference Call for the Organogenesis Holdings Inc. At this time, all participants have been placed in a listen-only mode. Please note that this conference call is being recorded and that the recording will be available on the company's website for replay shortly.

Organogenesis Holdings Inc. (ORGO) Q1 2023 Earnings Call Transcript

CANTON, Mass., May 10, 2023 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the first quarter ended March 31, 2023.

Organogenesis Holdings Inc. Reports First Quarter 2023 Financial Results

CANTON, Mass., April 27, 2023 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that its Board of Directors has elected President and Chief Executive Officer Gary S.

Organogenesis President and Chief Executive Officer Gary S. Gillheeney, Sr. Elected Chair of the Board of Directors

CANTON, Mass., April 10, 2023 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that first quarter of fiscal year 2023 financial results will be reported after the market closes on Wednesday, May 10th.

Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2023 Financial Results on May 10, 2023

Transitioning all skin substitutes to ASP-based payments has the potential to substantially reduce Medicare Part B expenditures Transitioning all skin substitutes to ASP-based payments has the potential to substantially reduce Medicare Part B expenditures

Organogenesis Applauds Findings from the Office of Inspector General

Motorcar Parts of America

Unisys

The S&P SmallCap 600 index dropped all three stocks.

Why Shares of Unisys, Organogenesis, and Motorcar Parts of America Fell Today

Organogenesis Holdings Inc. (NASDAQ:ORGO ) Q4 2022 Earnings Conference Call March 1, 2023 5:00 PM ET Company Participants Gary Gillheeney - President and Chief Executive Officer Dave Francisco - Chief Financial Officer Conference Call Participants Ryan Zimmerman - BTIG Operator Welcome, ladies and gentlemen to the Fourth Quarter and Fiscal Year 2022 Earnings Conference Call for Organogenesis Holdings Inc. [Operator Instructions] Please note that this conference call is being recorded and that the recording will be available on the company's website for replay shortly. Before we begin, I would like to remind everyone that our remarks today may contain forward-looking statements that are based on the current expectations of management and involve inherent risks and uncertainties that could cause actual results to differ materially from those indicated, including the risks and uncertainties described in the company's filings with the Securities and Exchange Commission, including Item 1A Risk Factors of the company's most recent annual report and its subsequently filed quarterly reports.

Organogenesis Holdings Inc. (ORGO) Q4 2022 Earnings Call Transcript

CANTON, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the fourth quarter and the year ended December 31, 2022.

Organogenesis Holdings Inc. Reports Fourth Quarter 2022 and Fiscal Year 2022 Financial Results; Introduces Fiscal Year 2023 Guidance

CANTON, Mass. , March 01, 2023 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today reported the favorable outcome of the interim analysis of its Phase 3 clinical trial for the management of symptoms associated with knee osteoarthritis.

Organogenesis Reports Positive Interim Analysis of Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis

CANTON, Mass., Feb. 09, 2023 (GLOBE NEWSWIRE) --  Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that fourth quarter and fiscal year 2022 financial results will be reported after the market closes on Wednesday, March 1st.

Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2022 Financial Results on March 1, 2023

Wilmington, Delaware--(Newsfile Corp. - January 19, 2023) - Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of Organogenesis Holdings Inc. (NASDAQ: ORGO) on behalf of stockholders.To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-organogenesis-holdings-inc.To contact Seth D. Rigrodsky or Gina M. Serra cost free, call or text (302) 295-5310 or email info@rl-legal.com.Rigrodsky Law, P.A.

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Organogenesis Holdings Inc.

CANTON, Mass., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that company management will participate in the Cantor Fitzgerald Medical and Aesthetic Dermatology, Ophthalmology and Medtech Conference, which is being held at The Fontainebleau Miami Beach in Miami, FL on Thursday, December 8th. The conference consists of panel discussions and 1x1 meetings with investors. Management will participate in 1x1 meetings.

News for Organogenesis Holdings Stock (ORGO)